Erin K. Brenner - Dec 9, 2022 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
Chief Product Dev. Officer
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Stock symbol
PEARQ
Transactions as of
Dec 9, 2022
Transactions value $
$15,000
Form type
4
Date filed
12/9/2022, 04:02 PM
Previous filing
May 27, 2022
Next filing
Jan 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PEARQ Common Stock Options Exercise $15K +15K +100% $1.00* 30K Dec 9, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Stock Option (Right to Buy) Options Exercise -15K -14.25% 90.2K Dec 9, 2022 Common Stock 15K $1.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to this option are fully vested and exercisable.
F2 Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 81,659 shares of common stock of Private Pear for $1.46 per share.